Latest Cannabidiol News

Page 1 of 3
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
ECS Botanics has delivered a fifth consecutive quarter of positive operating cash flow, while branded sales and international expansion continue to reshape the business. The next test is whether planned UK and Polish launches can convert into recurring revenue.
Ada Torres
Ada Torres
19 Oct 2026
Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.
Ada Torres
Ada Torres
31 Aug 2026
Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.
Ada Torres
Ada Torres
29 July 2026
Algorae Pharmaceuticals has independently validated its AlgoraeOS v2 platform, confirming improved accuracy in predicting synergistic drug combinations involving CBD across cancer models.
Victor Sage
Victor Sage
3 July 2026
Nexalis Therapeutics (ASX: NX1) has voluntarily suspended trading of its shares pending a material announcement on its existing debt funding facility, extending a recent trading halt. The suspension is set to last until the earlier of the announcement release or resumption of trading on 28 May 2026.
Ada Torres
Ada Torres
26 May 2026
Avecho Biotechnology has wrapped up the treatment phase for its pivotal Phase III insomnia trial involving 244 participants, setting the stage for an interim efficacy analysis expected in late June 2026.
Ada Torres
Ada Torres
21 May 2026
Algorae Pharmaceuticals has scaled its AI-driven drug synergy platform from one to 18 anchor drugs, generating over 9 million predictions and identifying thousands of promising combinations for cancer and other diseases.
Ada Torres
Ada Torres
18 May 2026
Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.
Ada Torres
Ada Torres
12 May 2026
Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.
Ada Torres
Ada Torres
29 Apr 2026
Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.
Ada Torres
Ada Torres
19 Mar 2026
Nexalis Therapeutics has initiated its Phase 1 trial for IRX-616a, an inhaled cannabidiol treatment aimed at panic disorder, marking a significant step in developing rapid-onset anxiety therapies.
Ada Torres
Ada Torres
4 Mar 2026

Browse the archive

Full archive